Year All202620252024202320222021202020192018 Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 March 4, 2025 Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference March 3, 2025 Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) January 8, 2025 Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 December 16, 2024 Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference November 25, 2024 Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain November 18, 2024 Contineum Therapeutics to Attend Upcoming Investor Conferences November 13, 2024 Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 6, 2024 Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences August 28, 2024 Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 13, 2024
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 March 4, 2025
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference March 3, 2025
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) January 8, 2025
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 December 16, 2024
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain November 18, 2024
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 6, 2024
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 13, 2024
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights